Hidradenocarcinoma: A Rare Skin Disease

Year : 2024 | Volume :02 | Issue : 01 | Page : 1-12

Aanchal Bhatia

Muskan Tiwari

Gaganpreet Kaur

  1. Student Department of Agricultural Biotechnology, Punjab Agricultural University (PAU), Ludhiana Punjab India
  2. Student Department of Agricultural Biotechnology, Punjab Agricultural University (PAU), Ludhiana Punjab India
  3. Assistant Professor Department of Agricultural Biotechnology, Punjab Agricultural University (PAU), Ludhiana Punjab India


Hidradenocarcinoma (HAC) also known as ‘‘sweat gland tumor” is an aggressive, uncommon, highly malignant, adnexal tumor derived from the intradermal duct of eccrine sweat glands. It is said to be aggressive as it has a high risk of local recurrence (50%–75%) and a high potential to metastasize to nearby lymph nodes or to other distant sites. Hidradenocarcinoma has other recognized variants which are known by different names such as Malignant Acrospiroma, Nodular Hidradenocarcinoma, Clear cell Hidradenocarcinoma, Malignant Nodular Hidradenoma, Malignant Clear Cell Hidradenoma, clear cell eccrine carcinoma or simply sweat gland tumor. However, the term Hidradenocarcinoma (HAC) is the recommended name. This malignant tumor arises from the eccrine glands which are located in sun-exposed locations. These malignancies exhibit a high reactivity to eccrine enzymatic stains and their morphologic features are seen under the electron microscope, so that’s why they are known to originate in the sweat glands. The occurrence rate is about 0.001% of all malignant tumors and Hidradenocarcinoma accounts for approximately 6% of malignant eccrine tumors, which in turn are found in 1:13,000 skin biopsies and <0.001% of all skin cancers. They usually appear de novo on healthy skin, or sometimes malignant transformation from their benign form. In 1865, French pathologist Victor Andre Cornil described the first case of sweat gland cancer. Hidradenocarcinoma (HAC) was first reported in 1948 in Brazil and was first described as a clear cell eccrine carcinoma by Keasby and Hadley in 1954. When Keasby first described this tumor in 1954 he found only 3 cases of hidradenocarcinoma among 235 sweat gland tumors.

Keywords: Tumor, Carcinoma, Hidradenocarcinoma, Hidradenoma, Malignant.

[This article belongs to International Journal of Cell Biology and Cellular Functions(ijcbcf)]

How to cite this article: Aanchal Bhatia, Muskan Tiwari, Gaganpreet Kaur. Hidradenocarcinoma: A Rare Skin Disease. International Journal of Cell Biology and Cellular Functions. 2024; 02(01):1-12.
How to cite this URL: Aanchal Bhatia, Muskan Tiwari, Gaganpreet Kaur. Hidradenocarcinoma: A Rare Skin Disease. International Journal of Cell Biology and Cellular Functions. 2024; 02(01):1-12. Available from: https://journals.stmjournals.com/ijcbcf/article=2024/view=145718

Browse Figures


  1. Kane B, Adler E, Bhandari T, Rose M, DiGuglielmo N, Sun X. Malignant hidradenocarcinoma in the lower extremity: a case report of a rare tumor. The Journal of Foot and Ankle Surgery. 2018 May 1;57(3):618–21.
  2. Mackenzie DH. A clear‐cell hidradenocarcinoma with metastases. Cancer. 1957 Sep;10(5):
  3. Ryu WC, Lee YH, Koh IC, Sohn JS, Jang SM. Hidradenocarcinoma of the Dorsum of the Hand. Chinese medical journal. 2017 Jul 20;130(14):1755–6.
  4. Singh R, Brewer J, Bernstein ZP, Donald Higgs MD. No sweat, a rare case of hidradenocarcinoma. The American Surgeon. 2012 Feb 1;78(2):E92.
  5. Lim J, Park SY, Lew H, Cho K. Hidradenocarcinoma on the orbit. The Nerve. 2018 Jan 18;4(1):16–9.
  6. Singh G, Narasimha A, Kumar H, Datti N. Clear cell hidradenocarcinoma of the eyelid: a case report with a review of the literature. International ophthalmology. 2013 Apr;33(2):171–5.
  7. Farooq U, Choudhary S, Russo J, Vincek V, Elgart G. Clear cell hidradenocarcinoma with helpful immunohistochemistry: a case report. International journal of dermatology. 2013 Nov;52(11):1380–2.
  8. Nazarian RM, Kapur P, Rakheja D, Piris A, Duncan LM, Mihm Jr MC, Hoang MP. Atypical and malignant hidradenomas: a histological and immunohistochemical study. Modern Pathology. 2009 Apr 1;22(4):600–10.
  9. Ko CJ, Cochran AJ, Eng W, Binder SW. Hidradenocarcinoma: a histological and immunohistochemical study. Journal of cutaneous pathology. 2006 Nov;33(11):726–30.
  10. Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW. Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature. Rare Tumors. 2015 Feb 25;7(1):29–33.
  11. Latorre A, Alghothani L, Lambert D, Jatana KR, Peters S, Foster J, Hill R. Mucin-producing malignant tumor of lower eyelid presenting in a 14-year-old patient. The Journal of Clinical and Aesthetic Dermatology. 2012 Apr;5(4):44.
  12. Nongkynrih A, Kamboj K, Dhull AK, Kaushal V. Miraculous response to radiotherapy in a rare case of malignant nodular hidradenoma nose. J Cancer Prev Curr Res. 2018;9(3):97–9.
  13. Wiedemeyer K, Brenn T. Malignant Skin Adnexal Tumors: Pathology and Genetics.
  14. KERSTING DW. Clear cell hidradenoma and hidradenocarcinoma. Archives of Dermatology. 1963 Mar 1;87(3):323–33.
  15. Patel N, Kramer A, Sun X. A Case of Clear Cell Hidradenoma Found During Abdominal Cyst Excision. Cureus. 2022 Mar 8;14(3).
  16. Ham T, Cheon SJ, Roh MS, Ha DH. Ultrasonography of malignant clear cell hidradenoma: a case report. Journal of the Korean Society of Radiology (Taehan Yŏngsang Ŭihakhoe chi). 2020 Mar;81(2):448.
  17. Ahn CS, Sangüeza OP. Malignant sweat gland tumors. Hematology/Oncology Clinics. 2019 Feb 1;33(1):53–71.
  18. Baklacı D, Kum RO, Yilmaz Y, Özcan M, Ünal A. An unusual tumor of the lower lip: benign nodular hidradenoma. ENTCase. 2017.
  19. Kazakov DV, Ivan D, Kutzner H, Spagnolo DV, Grossmann P, Vanecek T, Sima R, Kacerovska D, Shelekhova KV, Denisjuk N, Hillen U. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t (11; 19) translocation. The American journal of dermatopathology. 2009 May 1;31(3):236–47.
  20. Driscoll JJ, Gauerke S, Monahan BC. Mechanistic and Treatment Implications of Δ Np63 Expression in a Rare Case of Metastatic Hidradenocarcinoma. Case Reports in Oncology. 2009 Mar 14;2(1):44–52.
  21. An JK, Woo JJ, Hong YO. Malignant sweat gland tumor of breast arising in pre-existing benign tumor: a case report. World Journal of Clinical Cases. 2019 Oct 10;7(19):3033.
  22. Martins D, Pereira F, Azevedo R, Julião I. Eccrine hidradenocarcinoma of the scalp. Cureus. 2022 Mar 10;14(3).
  23. Khan BM, Mansha MA, Ali N, Abbasi AN, Ahmed SM, Qureshi BM, Abbasi AN. Hidradenocarcinoma: five years of local and systemic control of a rare sweat gland neoplasm with nodal metastasis. Cureus. 2018 Jun 26;10(6).
  24. Sanders DS, Carr RA. The use of immunohistochemistry in the differential diagnosis of common epithelial tumours of the skin. Current Diagnostic Pathology. 2007 Aug 1;13(4):237–51.
  25. Soni A, Bansal N, Kaushal V, Chauhan AK. Current management approach to hidradenocarcinoma: a comprehensive review of the literature. Ecancermedicalscience. 2015;9.
  26. Cleaveland P, Srivastava P, Oliveira P, Parnham A, Elliott T, Sangar V. A rare presentation of hidradenocarcinoma within the pênis. Urology Case Reports. 2019 Jan 1;22:57–9.
  27. Ohta M, Hiramoto M, Fujii M, Togo T. Nodular hidradenocarcinoma on the scalp of a young woman: case report and review of literature. Dermatologic surgery. 2004 Sep 1;30(9):1265–8.
  28. Elbenaye J, Moumine M, Sinaa M, Elhaouri M. Fatal hidradenocarcinoma of the scalp: A case report. European Annals of Otorhinolaryngology, Head and Neck Diseases. 2017 Apr 11;134(4):291–2.
  29. Holden B, Colome-Grimmer M, Savage C, Stierman K, Pou AM. Malignant eccrine acrospiroma with metastasis to the parotid. Ear, nose & throat journal. 2002 May;81(5):352–5.
  30. Son ET, Choi HJ, Lee HJ. Case report: clear cell hidradenocarcinoma of the nail bed. International Wound Journal. 2016 Oct;13(5):1067.
  31. Dillon C, Sevensma K, Morgan W. Treatment of Hidradenocarcinoma of the Scalp with Wide Local Excision: Case Report of a Rare and Malignant Tumor. Ann Clin Case Rep. 2019; 4.;1746.
  32. Stanciu A, Florica CE, Zota A, Tebeica T, Leventer M, Bobirca F. Surgical outcomes of more than 1300 cases of Mohs micrographic surgeries from a private Mohs clinic in Romania. Chirurgia (Bucur). 2020 Jan 1;115(1):69–79.
  33. Bedada AG, Georges A, Eshetu AB. Perianal malignant nodular hidradenoma in HIV infected pregnant patient. South African Journal of Surgery. 2018 Jun;56(2):64–6.

Regular Issue Subscription Case Study
Volume 02
Issue 01
Received February 15, 2024
Accepted February 29, 2024
Published May 9, 2024